Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme/BioMarin Aldurazyme approval

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Genzyme/BioMarin's orphan drug Aldurazyme (laronidase) clears FDA April 30 for treatment of the lysosomal disorder mucopolysaccharidosis I, based on a 26-week, 45-patient Phase III study. Labeling states that "Aldurazyme has been shown to improve pulmonary function and walking capacity [but] has not be evaluated for effects on the central nervous system manifestations of the disorder." Phase IV commitments include a patient registry, testing of urinary glycosaminoglycans and antibody levels, and assessment of a possible correlation "between endogenous enzyme activity and patient antibody responses and infusion reactions"; a dose optimization study is also planned. May launches are expected for Aldurazyme and Genzyme's Fabrazyme, which cleared FDA April 2

You may also be interested in...



Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.

Topics

UsernamePublicRestriction

Register

PS002241

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel